| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8735676 | Journal of Clinical and Experimental Hepatology | 2018 | 30 Pages |
Abstract
DAA therapy for HCV genotypes 1, 3 and 4 achieves high SVR rates in all patients, including those with cirrhosis and previous non-responders.
Keywords
DAAReal life experienceledipasvirLDVSOFSofosbuvirRVREASLSVR12RBVdcvSVRETRHCCmITTmodified intention-to-treatITTdirect acting antiviralsdaclatasvirRibavirinintention to treatdirect acting antiviralHepatitis CHBVHepatitis BHepatitis C virusHCVHIVRapid virological responsesustained virological responseend of treatment responseHepatocellular carcinoma
Related Topics
Health Sciences
Medicine and Dentistry
Hepatology
Authors
Varun Mehta, Ramit Mahajan, Vandana Midha, Vikram Narang, Kirandeep Kaur, Arshdeep Singh, Anand Malhotra, Aslam Parvez, Ajit Sood,